迈威生物-U (688062.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−17.4x

Market Cap

CNY 13.06B

MomentumView details →

1D Return

−6.22%

YTD Return

—

RSI (14)

39.6

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−17.4x

Market Cap

CNY 13.06B

RSI (14)

39.6

MomentumView details →

1D Return

−6.22%

YTD Return

—

ProfitabilityView details →

Gross Margin

88.61%

Net Margin

−123.38%

EBITDA Margin

−103.01%

ROE (TTM)

−860.88%

ROA (TTM)

−20.13%

Asset Turnover

0.16x

GrowthView details →

Revenue YoY

+321.05%

EPS YoY

+18.34%

FCF YoY

+57.17%

Revenue CAGR 3Y

+188.02%

EPS CAGR 3Y

+6.90%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

22.56x

Current Ratio

0.88x

Quick Ratio

0.79x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

745.32M

Net Income (TTM)

−919.55M

Op. CF (TTM)

−307.77M

Latest newsMore news →

Mabwell Bioscience reported its H1 2026 semi-annual results on August 30, with revenue of 313 million yuan (up 209.04% year-on-year) and a net loss attributable to shareholders of 522 million yuan, narrowing from a loss of 551 million yuan in the same period last year.5d ago

Mabwell (Shanghai) Bioscience Co., Ltd. received approval from the National Medical Products Administration for a clinical trial application of its 9MW5211 injection for vitiligo.51d ago

Similar companies

BioMarin Pharmaceutical Inc.BMRN Nanjing Leads Biolabs Co Ltd09887.HK Madrigal Pharmaceuticals, Inc.MDGL Halozyme Therapeutics, Inc.HALO 生物股份600201.SH Ascentage Pharma Group International06855.HK Find similar companies →

Latest newsMore news →

Mabwell Bioscience reported its H1 2026 semi-annual results on August 30, with revenue of 313 million yuan (up 209.04% year-on-year) and a net loss attributable to shareholders of 522 million yuan, narrowing from a loss of 551 million yuan in the same period last year.5d ago Mabwell (Shanghai) Bioscience Co., Ltd. received approval from the National Medical Products Administration for a clinical trial application of its 9MW5211 injection for vitiligo.51d ago